Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P19235

UPID:
EPOR_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P19235; B2RCG4; Q15443; Q2M205

BACKGROUND:
Erythropoietin receptor (EPOR) plays a critical role in red blood cell production by mediating the effects of erythropoietin. It triggers erythroblast proliferation and differentiation through the JAK2/STAT5 cascade upon EPO binding. EPOR's ability to also engage STAT1, STAT3, and LYN tyrosine kinase highlights its versatile signaling capabilities. The presence of EPOR-T isoform further regulates its signaling, illustrating the receptor's complex regulatory mechanisms.

THERAPEUTIC SIGNIFICANCE:
Given EPOR's key role in familial erythrocytosis, characterized by increased red blood cell counts without progression to leukemia, targeting EPOR offers a promising avenue for therapeutic intervention. Understanding EPOR's function and signaling pathways opens doors to developing targeted therapies for erythrocytosis and enhancing our approach to treating hematological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.